Authors discuss evidence-based research on
obesity, antibiotic resistance, and type 2 diabetes
BOSTON, April 19,
2024 /PRNewswire/ -- Today at ACP's annual meeting,
Internal Medicine Meeting 2024, Annals of Internal Medicine
presented three breaking scientific research articles during a live
scientific plenary session that featured the authors of those
articles. The articles were published in ACP's flagship journal
concurrent with the live meeting presentation. During the session,
New in Annals of Internal Medicine: Hear it First from the
Authors, the authors of two research studies addressing the
topics of obesity, antibiotic resistance, and an ACP clinical
guideline on type 2 diabetes presented their work to meeting
attendees.
During scientific plenary, authors
discussed studies on obesity, next-gen antibiotics, & ACP
clinical guideline on T2D.
Christine Laine, M.D., MPH,
Annals of Internal Medicine Editor-in-Chief and ACP Senior
Vice President, introduced the authors and facilitated a discussion
to gain further insights into their work. The articles and
presentations included:
- The Effect of Time-Restricted Eating on Body Weight: A
Randomized Controlled Isocaloric Feeding Trial in Adults with
Diabetes. Nisa Maruthur, M.D.,
MHS, Associate Professor of Medicine and Director of the General
Internal Medicine Fellowship Program at Johns
Hopkins discussed findings of a randomized controlled trial
of adults with obesity and prediabetes comparing time-restricted
eating and basic calorie control for weight loss. Dr. Maruthur
explained that when calories were held constant in both groups, it
did not seem to matter whether participants consumed most of their
calories early in the day or in the evening. Her findings suggest
that overall calories may be more important than meal timing when
it comes to weight loss.
- Assessing Clinical Utilization of Next Generation
Antibiotics Against Resistant Gram-negative Infections in US
Hospitals: A Retrospective Cohort Study. Sameer Kadri, M.D., MS, Tenure Track
Investigator in the National Institute of Health (NIH) Clinical
Center's Critical Care Medicine Department at the NIH Clinical
Center, explained that despite approval by the U.S. Food and Drug
Administration (FDA) for seven new gram-negative antibiotics
between 2014 and 2019, clinicians in U.S. hospitals still treated
more than 40 percent of patients battling highly resistant
pathogens exclusively with older, generic agents, even when these
older agents are already known to be highly toxic or sub-optimally
effective. Dr. Kadri told attendees that this sluggish uptake is an
important issue because it threatens future development and supply
of new antibiotics for patients.
- Newer Pharmacological Treatments in Adults with Type 2
Diabetes: A Clinical Guideline from the American College of
Physicians. Carolyn Crandall,
M.D. Professor of Medicine at the David Geffen School of Medicine
at UCLA and Chair of ACP's Clinical
Guidelines Committee, provided context and rationale for the
recommendations detailed in ACP's new diabetes guideline. Dr.
Crandall explained that ACP's guidelines are based on a systematic
review of the effectiveness and harms of newer pharmacological
treatments. The ACP guidelines committee prioritized clinical
benefit outcomes, such as reduced risk for mortality, stroke, and
myocardial infarction, over glycemic control, as all eligible
interventions, like sulfonylureas, GLP-1s, SGLT-2, DPP-4, and
long-acting insulins, are known to improve glycemic control in
adults with type 2 diabetes. This is a key difference between ACP
guidelines and those of other organizations. With this goal in
mind, ACP recommends adding a sodium-glucose cotransporter-2
(SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) agonist to
metformin and lifestyle interventions in adults with type 2
diabetes and inadequate glycemic control, she said. GLP-1 should be
considered when weight loss is an important treatment goal for the
patient.
"While this scientific plenary session marks a 'first' for ACP's
annual meeting, the topics discussed today are central to our work
as internal medicine physicians and on par with the high caliber of
research ACP members and Annals of Internal Medicine readers
have come to expect and anticipate every week," said Dr. Laine.
About the American College of Physicians
The American College of Physicians is the largest
medical specialty organization in the
United States with members in more than 145 countries
worldwide. ACP membership includes 161,000 internal medicine
physicians, related subspecialists, and medical students. Internal
medicine physicians are specialists who apply scientific knowledge
and clinical expertise to the diagnosis, treatment, and
compassionate care of adults across the spectrum from health to
complex illness. Follow ACP on X, Facebook,
Instagram and LinkedIn.
About Annals of Internal Medicine
Annals of Internal Medicine is the flagship journal
of the American College of Physicians
(ACP). Annals is the most widely read and
cited general internal medicine journal and one of the most
influential peer-reviewed clinical journals in the
world. Annals' mission is to promote excellence
in medicine, enable physicians and other health care professionals
to be well-informed members of the medical community and society,
advance standards in the conduct and reporting of medical research,
and contribute to improving the health of people worldwide. New
content is published every Tuesday at Annals.org. Follow
Annals on X and Instagram and
on Facebook.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/annals-of-internal-medicine-presents-breaking-scientific-news-at-acps-internal-medicine-meeting-2024-302122188.html
SOURCE American College of Physicians